Greetings! I am hoping to connect with organizations/facilities that serve the oncology population and have successfully eliminated injectable promethazine. The biggest area of concern/debate among some of our facilities is treatment of breakthrough nausea/vomiting in the oncology population.

I appreciate any information/pearls in this area others are willing to share. Also if you have a subject matter expert that would be willing to be contacted briefly by our team that would be appreciated!

Are patients required to be in negative pressure rooms for tobi nebs? Are there any other precautions around the administration of tobi nebs for inpatients at your facilities?

I am in communication with our system's respiratory council regarding a concern with sterile water for inhalation provided in flexible IV bags and the potential for incorrect IV administration as they appear very similar to standard IV bags. The product is used to provide humidification for a number of respiratory devices from the CareFusion AirLife line. Does anyone else have any experience with this product? Were any measures taken to distinguish the product from IV infusion therapies? Thanks

Has anyone completed a FMEA on the Box Picker or similar inventory management system that would share the findings? Much appreciated.

We are currently working on developing a downtime procedures for if/when our ADC (Pyxis) fails. If anyone is willing to share we would be greatful.
Thank you

Terrence Davidson BSP
Medication Safety Resource Pharmacist - Pharmacy Department
Royal University Hospital – Saskatoon Saskatchewan Canada
Saskatchewan Health Authority | 306-655-2274

We are focusing work in our ADC override rates and practices.

I wanted to verify how organizations were calculating their ADC override %s for metrics:

• # overrides / all ADC med vends or
• # overrides / all ADC vends for only meds that can be overridden

In creating tableau drilldowns by medication, I wanted to verify the denominator systems are using.

Thank you for weighing in!

Hi Everyone,

Is anyone willing to share their policies on a/b and ethanol locks? At our hospital, the CLABSI rate is increasing and we are reviewing if anyone is using a/b or ethanol locks different/prophylaxis for pts with documented central line infections. If you want you can post policy or protocols on discussion board or email pananthasingam@blythedale.org. Thank You for you help.

I'd be interested to know if anyone has any resource that has some basic questionnaires/tools to assess perceptions of medication safety climate among pharmacy team members. I beleive Knowing the baseline might give us pointers on how specifically to address further direction.
Thank you so much

Good Afternoon,

What strategies are you all employing to meet the updated NPSG.03.05.01 from The Joint Commission on anticoagulation that goes into effect July 1, 2019? Specifically around protocols/practice guidelines for reversal and perioperative management of anticoagulants.

Hi All
Our institution has recently completed a risk assessment on the use of epidurals in our L&D population (based on ISMP safety alert from 10/4/18). One of the recommendations from ISMP is to use 'unique neuraxial connectors.' When looking into these connectors (NRFit) it appears that they are 4x the cost of our typical epidural tubing (~$7/set vs ~$28/set).